← Back to Search

Telemedicine for Substance Use Disorders and HIV (HEAT Trial)

N/A

Waitlist Available

Led By Ellen F Eaton, MD, MSPH

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 month, 2 months, 3 months

Awards & highlights

No Placebo-Only Group

Summary

"This trial aims to address the increasing rates of substance use disorders and infectious diseases, such as HIV and hepatitis C, in rural parts of the U.S. where healthcare resources are limited. The study will

Who is the study for?

The HEAT Program is for individuals with substance use disorders, including opioid and stimulant use, who may also be living with or at risk for HIV. It's particularly focused on those in rural areas of the U.S. South where healthcare access is limited due to systemic issues like racism and lack of public health infrastructure.

What is being tested?

This trial is exploring how telemedicine can help people with substance use disorders receive better care, especially when they have or are at risk for HIV. The study compares standard in-person care to remote care via telemedicine to see if it improves access and outcomes.

What are the potential side effects?

Since this trial involves service delivery methods (standard of care vs. telemedicine), there aren't direct side effects like you'd expect from a drug trial. However, participants might experience technical difficulties or feel less satisfied with remote interactions compared to face-to-face visits.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 month, 2 months, 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 month, 2 months, 3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month, 2 months, 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Percent of participants who have a follow-up healthcare visit

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Patients living with HIV and substance useExperimental Treatment2 Interventions

Patients living with HIV and substance use, aged 18 and over. These participants are receiving services at HIV clinics in Alabama and must have reported opioid and/or stimulant misuse.

Do I qualify?Apply below to find out